Assembly Biosciences Announces $175M Equity Financings, Raises $19.60/Sh.

Assembly Biosciences has announced the pricing of a $175 million equity financing through the sale of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, accompanied by Class A and Class B warrants to purchase up to 6,632,660 shares of common stock at a combined price of $19.60 per share.

Assembly Biosciences (NASDAQ: ASMB), a biotechnology company focused on innovative small-molecule therapeutics for serious viral diseases, has announced the pricing of a $175 million equity financing round. The offering includes 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, accompanied by Class A and Class B warrants to purchase up to 6,632,660 shares of common stock at a combined price of $19.60 per share [1].

The financing round, which is expected to close on August 11, 2025, involves participation from new and existing investors, including Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, L.L.C., Janus Henderson Investors, RA Capital Management, and other healthcare dedicated funds [2]. Assembly Biosciences also announced a private placement with Gilead Sciences, Inc. for 2,295,920 shares of common stock and accompanying Class A and Class B warrants, under similar terms [3].

The proceeds from the offering and the private placement will be used for general corporate purposes, including advancing clinical trials and expanding research efforts. The company's latest press release highlights the significant investor confidence in Assembly Biosciences' potential, with notable participation from established investors [2].

References:
[1] https://seekingalpha.com/news/4482533-assembly-biosciences-announces-pricing-of-175-million-in-equity-financings
[2] https://www.nasdaq.com/press-release/assembly-biosciences-announces-pricing-175-million-equity-financings-2025-08-08
[3] https://www.ainvest.com/news/assembly-biosciences-raises-175m-equity-financing-2508/